Stock listing
Frankfurt:VF5 Ondine Biomedical, Inc. Aktie
German listing (Frankfurt) of Ondine Biomedical, Inc. · home listing LSE:OBI
Follow Ondine Biomedical, Inc. into a list and get an email when it puts out news.
Share price · FWB:VF5
€0.091 EUR -0.001 (-0.5%)
Close on Oct 30, 2026
- Day range
- €0.091 – €0.091 EUROct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:OBI · Home | 9.75p GBX (pence) | 0.00 (0.0%) | 195,218 | 9.625p | 9.75p | 9.50p | 9.75p | Close on Oct 30, 2026 |
| Frankfurt:VF5 | €0.091 EUR | -0.001 (-0.5%) | — | €0.091 | €0.091 | €0.091 | €0.092 | Close on Oct 30, 2026 |
- Ticker
- Frankfurt:VF5
- Asset type
- Stock
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 28, 2026
LANTERN Safety Results Presented at IDWeek
Latest earnings call · Sep 10, 2026
Ondine Biomedical (LSE:OBI) — Investor Presentation of Phase 3 Topline Results
Replay and transcript
Calls
Replays
Ondine Biomedical (LSE:OBI) — Investor Presentation of Phase 3 Topline Results
Thu, Sep 10, 2026 · 11:30 AM ET
Watch TranscriptOndine Biomedical (LSE:OBI) — Results for the year ended 31 December 2025
Thu, Jun 04, 2026 · 11:30 AM ET
Watch TranscriptOndine Biomedical (LSE:OBI) — Interim financial results for the period ended 30 June 2025
Fri, Sep 26, 2025 · 11:30 AM ET
Watch Transcript
Latest news
Financings
Private placement of new Common Shares
Oct 20, 2026 · US$13.31M
Update: £10M · £0.1 a share · Peel Hunt LLP +2
Dealers: Peel Hunt LLP (lead), Orana Corporate LLP, Strand Hanson Limited
Buyers: Carolyn Cross (10,593,220 Subscription Shares for approximately £1.06 million)
Insiders: CEO Carolyn Cross subscribed for 10,593,220 Subscription Shares for about £1.06 million; other Directors subscribed for 1,141,464 Subscription Shares, about £0.11 million, through amounts owed to them
Use of proceeds: Expand sales and business development, and advance regulatory, manufacturing and submission work for a planned NDA submission in mid-2027
Common shares
Sep 30, 2026
Announced: raise
Use of proceeds: Publishing full LANTERN trial analyses, FDA engagement toward a mid-2027 NDA, commercial pilots, sales and marketing, and working capital
Ondine Biomedical, Inc. on 6ix
- News releases
- 44 in the last 12 months · 210 in all · newest Oct 28, 2026 · oldest 2021
- Calls
- 9 calls with a replay · 9 with a transcript · latest Sep 10, 2026
Where Ondine Biomedical, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:OBI · Home listing | LSE | United Kingdom | GBX |
| OTC:OBIMF | OTC | United States | USD |
| Frankfurt:VF5 · This page | Frankfurt | Germany | EUR |
Log in to ask 6ix AI your own questions about Ondine Biomedical, Inc.